| |
| |
|
| Insider
Information: |
Eastham Karin |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
195,379 |
|
|
Indirect Shares
|
1,000 |
|
|
| Direct
Value |
$2,329,476 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
196,379 |
|
|
| Total
Value |
$2,329,476 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Diversa Corp |
VRNM |
Sr. VP Finance, CFO & ... |
2004-04-29 |
6,419 |
2004-04-29 |
1,000 |
Premium* |
|
|
Sgx Pharmaceuticals, Inc. |
SGXP |
Director |
2008-08-20 |
0 |
|
0 |
Premium* |
|
|
Illumina Inc |
ILMN |
Director |
2019-05-23 |
10,049 |
2008-05-16 |
0 |
Premium* |
|
|
Geron Corporation |
GERN |
Director |
2023-01-13 |
109,047 |
2009-05-29 |
0 |
Premium* |
|
|
Trius Therapeutics Inc |
TSRX |
Director |
2013-09-11 |
0 |
2013-09-11 |
0 |
Premium* |
|
|
Amylin Pharmaceuticals Inc |
AMLN |
Director |
2012-08-08 |
0 |
2011-05-24 |
0 |
Premium* |
|
|
Veracyte, Inc. |
VCYT |
Director |
2024-04-01 |
33,125 |
2021-11-01 |
0 |
Premium* |
|
|
Nektar Therapeutics |
NKTR |
Director |
2022-09-16 |
23,233 |
2018-09-27 |
0 |
Premium* |
|
|
Personalis, Inc. |
PSNL |
Director |
2022-05-17 |
13,506 |
2021-05-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2024-04-01 |
4 |
AS |
$21.65 |
$216,528 |
D/D |
(10,000) |
33,125 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2024-04-01 |
4 |
OE |
$13.19 |
$131,900 |
D/D |
10,000 |
43,125 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
9,674 |
33,125 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2023-03-16 |
4 |
AS |
$22.78 |
$427,044 |
D/D |
(18,750) |
23,451 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2023-03-16 |
4 |
OE |
$12.12 |
$227,250 |
D/D |
18,750 |
42,201 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2023-02-28 |
4 |
AS |
$25.00 |
$250,001 |
D/D |
(10,000) |
23,451 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2023-02-28 |
4 |
OE |
$12.12 |
$121,200 |
D/D |
10,000 |
33,451 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2023-01-13 |
4 |
OE |
$1.10 |
$38,500 |
D/D |
35,000 |
109,047 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
23,233 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
Director |
– • – |
2022-09-13 |
4 |
AS |
$3.61 |
$76,774 |
D/D |
(21,267) |
13,033 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
14,731 |
23,451 |
0 |
- |
|
| PSNL |
Personalis, Inc. |
Director |
– • – |
2022-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
10,770 |
13,506 |
0 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2022-04-20 |
4 |
OE |
$1.41 |
$49,350 |
D/D |
35,000 |
74,047 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-12-17 |
4 |
AS |
$45.00 |
$225,000 |
D/D |
(5,000) |
8,720 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-12-17 |
4 |
OE |
$12.12 |
$60,600 |
D/D |
5,000 |
13,720 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-11-01 |
4 |
AS |
$47.73 |
$145,106,339 |
I/I |
(4,400) |
0 |
0 |
% |
|
| NKTR |
Nektar Therapeutics |
Director |
– • – |
2021-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
10,200 |
34,300 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-08-02 |
4 |
AS |
$43.54 |
$193,194 |
I/I |
(4,400) |
4,400 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
8,720 |
8,720 |
0 |
- |
|
| PSNL |
Personalis, Inc. |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
2,736 |
0 |
- |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-05-03 |
4 |
AS |
$48.01 |
$213,700 |
I/I |
(4,427) |
8,800 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-02-25 |
4 |
AS |
$60.03 |
$379,359 |
D/D |
(6,250) |
0 |
0 |
% |
|
| VCYT |
Veracyte, Inc. |
Director |
– • – |
2021-02-25 |
4 |
OE |
$4.00 |
$25,000 |
D/D |
6,250 |
6,250 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
Director |
– • – |
2020-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
24,100 |
0 |
- |
|
| NKTR |
Nektar Therapeutics |
Director |
– • – |
2019-09-25 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
15,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
